ABCL News and Press, AbCellera Biologics Inc. From 02/25/22

Image source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL) Q4 2021 Earnings Call Feb 24, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics Inc. (ABCL) Q4 2021 Earnings Call Transcript ...

Abcellera Biologics, Inc. Q4 2021 Earnings Conference Call Feb 24, 2022 05:00 PM ET Company Participants Tryn Stimart - Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Carl Hansen - President and CEO Andrew Booth - CFO Conference Call Participants Stephen Willey - Stif...

The following slide deck was published by AbCellera Biologics Inc. in conjunction with their 2021 Q4 earnings call. For further details see: AbCellera Biologics Inc. 2021 Q4 - Results - Earnings Call Presentation

AbCellera Biologics press release (NASDAQ:ABCL): Q4 GAAP EPS of $0.19 beats by $0.01. Revenue of $139.3M beats by $17.44M. “In 2021 we made significant advancements in executing our long-term strategy by growing our portfolio, deepening our platform to unlock new modalities, and expand...

Total revenue of $375 million, up from $233 million in 2020, and liquidity of over $720 million Total cumulative program starts of 78, with 26 new starts in the year EPS of $0.56 (basic) and $0.48 (diluted) compared to $0.53 (basic) and $0.45 (diluted) per share in 2...

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will participate in a panel during the Truist Securities AI Symposium – Biotech & Tools. The panel is titled, “Integrated Platforms for AI-based Drug Discovery,” and will take place vi...

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 12:40 p.m. Pacific Time. A live audio webcast of the presentation may be accessed throu...

Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data Previously reported data show that bebtelovimab has broad and potent neutralization of all other known circulating SARS-CoV-2 variants of ...

AbCellera announced on Thursday Feb 10th a supply deal with the US government and Lilly for Bebtelovimab, the AbCellera developed pan COVID variant antibody treatment. The supply deal includes an initial 600,000 doses valued at $720 million with an option for an additional 500,000 dos...

Bebtelovimab neutralizes Omicron, including subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data AbCellera (Nasdaq: ABCL) today announced Eli Lilly and Company (Lilly) has entered into a purchase agreement with the U.S. government to supply up to 6...